Premium
The impact of cancer drug wastage on economic evaluations
Author(s) -
Truong Judy,
Cheung Matthew C.,
Mai Helen,
Letargo Jessa,
Chambers Alexandra,
Sabharwal Mona,
Trudeau Maureen E.,
Chan Kelvin K. W.
Publication year - 2017
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30807
Subject(s) - medicine , body surface area , dosing , drug , body weight , total cost , emergency medicine , operations management , surgery , pharmacology , accounting , economics , business
BACKGROUND The objective of this study was to determine the impact of modeling cancer drug wastage in economic evaluations because wastage can result from single‐dose vials on account of body surface area– or weight‐based dosing. METHODS Intravenous chemotherapy drugs were identified from the pan‐Canadian Oncology Drug Review (pCODR) program as of January 2015. Economic evaluations performed by drug manufacturers and pCODR were reviewed. Cost‐effectiveness analyses and budget impact analyses were conducted for no‐wastage and maximum‐wastage scenarios (ie, the entire unused portion of the vial was discarded at each infusion). Sensitivity analyses were performed for a range of body surface areas and weights. RESULTS Twelve drugs used for 17 indications were analyzed. Wastage was reported (ie, assumptions were explicit) in 71% of the models and was incorporated into 53% by manufacturers; this resulted in a mean incremental cost‐effectiveness ratio increase of 6.1% (range, 1.3%‐14.6%). pCODR reported and incorporated wastage for 59% of the models, and this resulted in a mean incremental cost‐effectiveness ratio increase of 15.0% (range, 2.6%‐48.2%). In the maximum‐wastage scenario, there was a mean increase in the incremental cost‐effectiveness ratio of 24.0% (range, 0.0%‐97.2%), a mean increase in the 3‐year total incremental budget costs of 26.0% (range, 0.0%‐83.1%), and an increase in the 3‐year total incremental drug budget cost of approximately CaD $102 million nationally. Changing the mean body surface area or body weight caused 45% of the drugs to have a change in the vial size and/or quantity, and this resulted in increased drug costs. CONCLUSIONS Cancer drug wastage can increase drug costs but is not uniformly modeled in economic evaluations. Cancer 2017;123:3583‐90. © 2017 American Cancer Society .